Delayed
Hong Kong S.E.
22:53:21 2024-07-03 EDT
|
5-day change
|
1st Jan Change
|
0.73
HKD
|
-6.41%
|
|
-7.32%
|
-67.24%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,139
|
1,117
|
1,039
|
756.2
|
603.5
|
201.9
|
-
|
-
|
Enterprise Value (EV)
1 |
931.9
|
905.3
|
894.7
|
717.6
|
631.8
|
294.8
|
288
|
274.6
|
P/E ratio
|
61.7
x
|
66.2
x
|
58.2
x
|
30.2
x
|
57.1
x
|
11.9
x
|
7.87
x
|
8.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11.3
x
|
8.88
x
|
5.64
x
|
3.02
x
|
2.32
x
|
0.68
x
|
0.58
x
|
0.49
x
|
EV / Revenue
|
9.28
x
|
7.2
x
|
4.85
x
|
2.87
x
|
2.43
x
|
0.99
x
|
0.83
x
|
0.67
x
|
EV / EBITDA
|
36.7
x
|
38.1
x
|
20.6
x
|
13.1
x
|
10
x
|
5.23
x
|
4.37
x
|
4.14
x
|
EV / FCF
|
160
x
|
54.7
x
|
-14.2
x
|
48.6
x
|
-
|
10.4
x
|
9.99
x
|
-66.8
x
|
FCF Yield
|
0.63%
|
1.83%
|
-7.03%
|
2.06%
|
-
|
9.63%
|
10%
|
-1.5%
|
Price to Book
|
4.3
x
|
3.89
x
|
3.25
x
|
2.29
x
|
1.76
x
|
0.56
x
|
0.54
x
|
0.51
x
|
Nbr of stocks (in thousands)
|
2,007,641
|
2,033,549
|
2,051,280
|
2,036,428
|
2,031,318
|
2,022,246
|
-
|
-
|
Reference price
2 |
0.5674
|
0.5495
|
0.5067
|
0.3713
|
0.2971
|
0.0999
|
0.0999
|
0.0999
|
Announcement Date
|
20-03-30
|
21-03-29
|
22-03-28
|
23-03-28
|
24-03-28
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
100.4
|
125.8
|
184.4
|
250.4
|
259.9
|
298.4
|
345.8
|
410.3
|
EBITDA
1 |
25.36
|
23.77
|
43.51
|
54.66
|
63.2
|
56.39
|
65.86
|
66.38
|
EBIT
1 |
21.07
|
15.75
|
25.83
|
33.68
|
19.63
|
28.45
|
38.01
|
45.01
|
Operating Margin
|
20.99%
|
12.52%
|
14%
|
13.45%
|
7.55%
|
9.53%
|
10.99%
|
10.97%
|
Earnings before Tax (EBT)
1 |
20.86
|
19.52
|
25.07
|
36.1
|
14.58
|
24.37
|
34.11
|
41.69
|
Net income
1 |
18.42
|
17.15
|
18.43
|
25.74
|
10.81
|
17.89
|
25.19
|
30.8
|
Net margin
|
18.35%
|
13.63%
|
9.99%
|
10.28%
|
4.16%
|
6%
|
7.28%
|
7.51%
|
EPS
2 |
0.009200
|
0.008300
|
0.008700
|
0.0123
|
0.005200
|
0.008360
|
0.0127
|
0.0114
|
Free Cash Flow
1 |
5.833
|
16.55
|
-62.89
|
14.78
|
-
|
28.37
|
28.85
|
-4.108
|
FCF margin
|
5.81%
|
13.16%
|
-34.1%
|
5.9%
|
-
|
9.51%
|
8.34%
|
-1%
|
FCF Conversion (EBITDA)
|
23%
|
69.65%
|
-
|
27.04%
|
-
|
50.32%
|
43.8%
|
-
|
FCF Conversion (Net income)
|
31.66%
|
96.52%
|
-
|
57.42%
|
-
|
158.6%
|
114.52%
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-30
|
21-03-29
|
22-03-28
|
23-03-28
|
24-03-28
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
---|
Net sales
1 |
50.73
|
50.66
|
75.15
|
85.12
|
99.32
|
118.9
|
131.4
|
128.4
|
131.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
12.01
|
13.82
|
17.54
|
16.14
|
8.98
|
10.65
|
Operating Margin
|
-
|
-
|
-
|
14.1%
|
13.92%
|
14.75%
|
12.28%
|
7%
|
8.1%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
0.004200
|
0.004500
|
0.006100
|
0.006200
|
0.002200
|
0.003000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-30
|
20-08-28
|
21-03-29
|
21-08-25
|
22-03-28
|
22-08-25
|
23-03-28
|
23-08-25
|
24-03-28
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
28.3
|
92.9
|
86.1
|
72.6
|
Net Cash position
1 |
207
|
212
|
145
|
38.6
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.447
x
|
1.647
x
|
1.307
x
|
1.094
x
|
Free Cash Flow
1 |
5.83
|
16.6
|
-62.9
|
14.8
|
-
|
28.4
|
28.8
|
-4.11
|
ROE (net income / shareholders' equity)
|
12%
|
6.21%
|
6.06%
|
7.88%
|
3.2%
|
5.5%
|
6.29%
|
7.51%
|
ROA (Net income/ Total Assets)
|
9.38%
|
4.93%
|
4.29%
|
5.01%
|
1.93%
|
3.24%
|
3.95%
|
4.64%
|
Assets
1 |
196.4
|
347.7
|
429.3
|
513.2
|
561.2
|
551.5
|
638.5
|
663.3
|
Book Value Per Share
2 |
0.1300
|
0.1400
|
0.1600
|
0.1600
|
0.1700
|
0.1800
|
0.1900
|
0.2000
|
Cash Flow per Share
2 |
0.0100
|
0.0200
|
0.0200
|
0.0300
|
0.0200
|
0.0200
|
0.0200
|
0.0300
|
Capex
1 |
13.9
|
15.1
|
50.6
|
47.7
|
-
|
36.3
|
38.4
|
41.3
|
Capex / Sales
|
13.84%
|
12%
|
27.43%
|
19.04%
|
-
|
12.15%
|
11.09%
|
10.05%
|
Announcement Date
|
20-03-30
|
21-03-29
|
22-03-28
|
23-03-28
|
24-03-28
|
-
|
-
|
-
|
Last Close Price
0.0999
USD Average target price
0.2178
USD Spread / Average Target +118.13% Consensus |
1st Jan change
|
Capi.
|
---|
| -67.24% | 189M | | +16.59% | 44.87B | | -10.62% | 37.8B | | +40.49% | 37.61B | | +29.92% | 31.32B | | -9.78% | 27.4B | | +12.34% | 26.32B | | +41.53% | 14.07B | | +31.49% | 12.5B | | -7.40% | 11.23B |
Other Biotechnology & Medical Research
|